초록 ▼

The invention provides saponin mixtures and compounds which are isolated from the species Acacia victoriae and methods for their use. These compounds may contain a triterpene moiety, such as acacic or oleanolic acid, to which oligosaccharides and monoterpenoid moieties are attached. The mixtures and

The invention provides saponin mixtures and compounds which are isolated from the species Acacia victoriae and methods for their use. These compounds may contain a triterpene moiety, such as acacic or oleanolic acid, to which oligosaccharides and monoterpenoid moieties are attached. The mixtures and compounds have properties related to the regulation of apoptosis and cytotoxicity of cells and exhibit potent anti-tumor effects against a variety of tumor cells.

대표청구항 ▼

1. A pharmaceutical composition comprising a compound having the molecular formula: wherein R1 and R2 each comprise an oligosaccharide; andwherein R3 is selected from the group consisting of hydrogen, C1-C5 alkyl, C1-C5 alkylene, C1-C5 alkyl carbonyl, and wherein R5 is selected from the group consis

1. A pharmaceutical composition comprising a compound having the molecular formula: wherein R1 and R2 each comprise an oligosaccharide; andwherein R3 is selected from the group consisting of hydrogen, C1-C5 alkyl, C1-C5 alkylene, C1-C5 alkyl carbonyl, and wherein R5 is selected from the group consisting of hydrogen, hydroxyl, C1-C5 alkyl, C1-C5 alkylene, C1-C5 alkyl carbonyl, a sugar, C1-C5 alkyl ester, and a monoterpene group. 2. The composition of claim 1, wherein the compound has the molecular formula: 3. The composition of claim 1, wherein the pharmaceutical composition is formulated for parenteral administration, oral administration, topical administration, or aerosol delivery. 4. The composition of claim 3, wherein the pharmaceutical composition is formulated for parenteral administration. 5. The composition of claim 4, wherein the pharmaceutical composition is formulated for intravenous, intramuscular, subcutaneous, or intratumoral administration. 6. The composition of claim 3, wherein the pharmaceutical composition is formulated for topical administration. 7. The composition of claim 1, wherein R1 and R2 each comprise a monosaccharide, a disaccharide, a trisaccharide or a tetrasaccharide. 8. The composition of claim 7, wherein R1 and R2 each comprise an oligosaccharide comprising sugars which are separately and independently selected from the group consisting of glucose, fucose, rhamnose, arabinose, xylose, quinovose, maltose, glucuronic acid, ribose, N-acetyl glucosamine, and galactose. 9. The composition of claim 8, wherein at least one sugar is methylated. 10. The composition of claim 1, wherein R3 is hydrogen. 11. The composition of claim 10, wherein R1 is an oligosaccharide comprising N-acetyl glucosamine, fucose and xylose; and R2 is an oligosaccharide comprising glucose, arabinose and rhamnose. 12. The composition of claim 1, wherein R1 is an oligosaccharide comprising N-acetyl glucosamine, fucose and xylose; and R2 is an oligosaccharide comprising glucose, arabinose and rhamnose. 13. The composition of claim 12, wherein the compound has the molecular formula: 14. The composition of claim 1, wherein R3 is selected from the group consisting of 15. The composition of claim 1, wherein the compound has the molecular formula: 16. The composition of claim 15, having the molecular formula: